149 reports of this reaction
2.3% of all CEFADROXIL reports
#12 most reported adverse reaction
RESPIRATORY TRACT INFECTION is the #12 most commonly reported adverse reaction for CEFADROXIL, manufactured by Aurobindo Pharma Limited. There are 149 FDA adverse event reports linking CEFADROXIL to RESPIRATORY TRACT INFECTION. This represents approximately 2.3% of all 6,348 adverse event reports for this drug.
Patients taking CEFADROXIL who experience respiratory tract infection should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RESPIRATORY TRACT INFECTION is a less commonly reported adverse event for CEFADROXIL, but still significant enough to appear in the safety profile.
In addition to respiratory tract infection, the following adverse reactions have been reported for CEFADROXIL:
The following drugs have also been linked to respiratory tract infection in FDA adverse event reports:
RESPIRATORY TRACT INFECTION has been reported as an adverse event in 149 FDA reports for CEFADROXIL. This does not prove causation, but indicates an association observed in post-market surveillance data.
RESPIRATORY TRACT INFECTION accounts for approximately 2.3% of all adverse event reports for CEFADROXIL, making it a notable side effect.
If you experience respiratory tract infection while taking CEFADROXIL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.